Sparsentan reduces proteinuria, slows kidney decline in pediatric FSGS #KidneyWk www.healio.com/news/nephrol...
Sparsentan reduces proteinuria, slows kidney decline in pediatric FSGS
HOUSTON — Sparsentan therapy was associated with sustained decline in proteinuria and lower likelihood of progression to kidney failure vs. irbesartan for pediatric patients with focal segmental glome...
www.healio.com
November 8, 2025 at 1:45 AM
Sparsentan reduces proteinuria, slows kidney decline in pediatric FSGS #KidneyWk www.healio.com/news/nephrol...
Cellular variant of focal segmental glomerulosclerosis, with endocapillary hypercellularity with foam cells and mononuclear cells (top; Jones silver stain)"
bit.ly/4nNJdy2 (FREE)
#renalpath #FSGS
bit.ly/4nNJdy2 (FREE)
#renalpath #FSGS
November 9, 2025 at 11:00 AM
Cellular variant of focal segmental glomerulosclerosis, with endocapillary hypercellularity with foam cells and mononuclear cells (top; Jones silver stain)"
bit.ly/4nNJdy2 (FREE)
#renalpath #FSGS
bit.ly/4nNJdy2 (FREE)
#renalpath #FSGS
FREE The tip lesion variant of focal segmental glomerulosclerosis (FSGS) is associated with nephrotic syndrome and usually responds to steroid therapy. This #FSGS variant has the lowest risk for progression to kidney failure.
bit.ly/47tgF8l #RenalPath
bit.ly/47tgF8l #RenalPath
November 2, 2025 at 11:00 AM
FREE The tip lesion variant of focal segmental glomerulosclerosis (FSGS) is associated with nephrotic syndrome and usually responds to steroid therapy. This #FSGS variant has the lowest risk for progression to kidney failure.
bit.ly/47tgF8l #RenalPath
bit.ly/47tgF8l #RenalPath
Special situations:
IgA with Nephrotic syndrome: presentation is rare but associated with podocytopathy.
Treat according to the histological pattern and clinical presentation.
With the impending approval of DEARAs for FSGS, should it be first line in these patients?
#NephJC
IgA with Nephrotic syndrome: presentation is rare but associated with podocytopathy.
Treat according to the histological pattern and clinical presentation.
With the impending approval of DEARAs for FSGS, should it be first line in these patients?
#NephJC
October 29, 2025 at 1:30 AM
Special situations:
IgA with Nephrotic syndrome: presentation is rare but associated with podocytopathy.
Treat according to the histological pattern and clinical presentation.
With the impending approval of DEARAs for FSGS, should it be first line in these patients?
#NephJC
IgA with Nephrotic syndrome: presentation is rare but associated with podocytopathy.
Treat according to the histological pattern and clinical presentation.
With the impending approval of DEARAs for FSGS, should it be first line in these patients?
#NephJC
Mineralocorticoid receptor inhibition in parietal epithelial cells prevents focal segmental glomerulosclerosis and crescentic glomerulonephritis.
doi.org/10.1016/j.kint.2025.07.037
#OpenAccess #NephSky #MedSky #CKD #FSGS #chronickidneydisease @parcc-inserm.bsky.social @rwth.bsky.social
doi.org/10.1016/j.kint.2025.07.037
#OpenAccess #NephSky #MedSky #CKD #FSGS #chronickidneydisease @parcc-inserm.bsky.social @rwth.bsky.social
October 6, 2025 at 4:19 PM
Mineralocorticoid receptor inhibition in parietal epithelial cells prevents focal segmental glomerulosclerosis and crescentic glomerulonephritis.
doi.org/10.1016/j.kint.2025.07.037
#OpenAccess #NephSky #MedSky #CKD #FSGS #chronickidneydisease @parcc-inserm.bsky.social @rwth.bsky.social
doi.org/10.1016/j.kint.2025.07.037
#OpenAccess #NephSky #MedSky #CKD #FSGS #chronickidneydisease @parcc-inserm.bsky.social @rwth.bsky.social
PARASOL Project is expanding focus to include biomarkers & endpoints in APOL1 kidney disease and primary MN as well as FSGS. Learn more: eu1.hubs.ly/H0nr8Lv0
@tobias-b-huber.bsky.social @miktmc.bsky.social @jarcyzphd.bsky.social @ohiostatemed.bsky.social @utoronto.ca @nu-nephrology.bsky.social
@tobias-b-huber.bsky.social @miktmc.bsky.social @jarcyzphd.bsky.social @ohiostatemed.bsky.social @utoronto.ca @nu-nephrology.bsky.social
PARASOL Project Expands Focus to APOL1, Membranous Nephropathy
PARASOL Project expands to focus on APOL1 kidney disease and primary membranous nephropathy, aiming to improve clinical trial endpoints for these conditions.
eu1.hubs.ly
October 3, 2025 at 1:35 PM
How do we develop RCT that are feasible and reach actionable (approvable) conclusions. She says that FSGS is a disease that has not been well serviced by traditional 1:1 RCTs
Suggests umbrella trials looking at multiple agents. #GlomCon
Suggests umbrella trials looking at multiple agents. #GlomCon
September 24, 2025 at 6:35 PM
How do we develop RCT that are feasible and reach actionable (approvable) conclusions. She says that FSGS is a disease that has not been well serviced by traditional 1:1 RCTs
Suggests umbrella trials looking at multiple agents. #GlomCon
Suggests umbrella trials looking at multiple agents. #GlomCon
EM showed diffuse foot process effacement
dx diffuse podocytopathy with early FSGS most likely representing primary FSGS
He wants to discuss treatment
Started on prednisone at 60 mg, protienura from 9 to 3.5 g then dose decreased to 40 mg and patient has a recurrence. #GlomCon
dx diffuse podocytopathy with early FSGS most likely representing primary FSGS
He wants to discuss treatment
Started on prednisone at 60 mg, protienura from 9 to 3.5 g then dose decreased to 40 mg and patient has a recurrence. #GlomCon
September 24, 2025 at 12:43 AM
EM showed diffuse foot process effacement
dx diffuse podocytopathy with early FSGS most likely representing primary FSGS
He wants to discuss treatment
Started on prednisone at 60 mg, protienura from 9 to 3.5 g then dose decreased to 40 mg and patient has a recurrence. #GlomCon
dx diffuse podocytopathy with early FSGS most likely representing primary FSGS
He wants to discuss treatment
Started on prednisone at 60 mg, protienura from 9 to 3.5 g then dose decreased to 40 mg and patient has a recurrence. #GlomCon
Did You Miss The Broadcast With MARC CORONEL, Kidney Transplant Recipient, FSGS Patient, Active Kidney Advocate, THE KIDNEY FIGHTER, Keynote Speaker, Patient Advocacy Leader, Published Writer! Catch The Instant Replay Here! PLEASE LIKE AND SHARE!
www.youtube.com/live/K10sAyp...
www.youtube.com/live/K10sAyp...
January 25, 2025 at 3:12 AM
Did You Miss The Broadcast With MARC CORONEL, Kidney Transplant Recipient, FSGS Patient, Active Kidney Advocate, THE KIDNEY FIGHTER, Keynote Speaker, Patient Advocacy Leader, Published Writer! Catch The Instant Replay Here! PLEASE LIKE AND SHARE!
www.youtube.com/live/K10sAyp...
www.youtube.com/live/K10sAyp...
Breaking News: ( NASDAQ: #TVTX ) Travere Therapeutics to Submit sNDA for FILSPARI (sparsentan) in FSGS
February 11, 2025 at 7:01 PM
Breaking News: ( NASDAQ: #TVTX ) Travere Therapeutics to Submit sNDA for FILSPARI (sparsentan) in FSGS
LDL-apheresis in FSGS, how does it work? Unknown, but a few possibilities:
1. Inhibition of binding sites for our FSGS meds
2. ?epitopes that bind anti-nephrin Ab
3. Chemotactic factor
#rarekidneydiseaseconference #lluneph
1. Inhibition of binding sites for our FSGS meds
2. ?epitopes that bind anti-nephrin Ab
3. Chemotactic factor
#rarekidneydiseaseconference #lluneph
December 8, 2024 at 8:12 PM
LDL-apheresis in FSGS, how does it work? Unknown, but a few possibilities:
1. Inhibition of binding sites for our FSGS meds
2. ?epitopes that bind anti-nephrin Ab
3. Chemotactic factor
#rarekidneydiseaseconference #lluneph
1. Inhibition of binding sites for our FSGS meds
2. ?epitopes that bind anti-nephrin Ab
3. Chemotactic factor
#rarekidneydiseaseconference #lluneph
#TVTX Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025
https://www.stocktitan.net/news/TVTX/travere-therapeutics-announces-late-breaking-data-from-phase-3-e8ie017516ms.html
https://www.stocktitan.net/news/TVTX/travere-therapeutics-announces-late-breaking-data-from-phase-3-e8ie017516ms.html
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025
Travere Therapeutics (Nasdaq: TVTX) presented late-breaking Phase 3 DUPLEX data at ASN Kidney Week 2025 (Nov 6-9). The analyses show FILSPARI (sparsentan) patients were more likely to reach urine protein-to-creatinine ratio (UPCR) below 0.7 g/g versus maximum labeled dose irbesartan (37.5% vs 21.4%, RR 1.8).At week 108, rates were 19% vs 11.2% (RR 1.7). DUPLEX-aligned RaDaR modeling linked achieving UPCR24% lower 5-year kidney-failure risk (HR 0.76).
www.stocktitan.net
November 6, 2025 at 4:00 PM
#TVTX Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025
https://www.stocktitan.net/news/TVTX/travere-therapeutics-announces-late-breaking-data-from-phase-3-e8ie017516ms.html
https://www.stocktitan.net/news/TVTX/travere-therapeutics-announces-late-breaking-data-from-phase-3-e8ie017516ms.html
I have a patient, he is a manager at a fast food restaurant. He had frequently relapsing minimal change disease as a kid and now has FSGS. We are treating him with MMF. He has health insurance. His out of pocket cost for MMF went zero dollars to $1000 a month. He stopped the MMF.
December 2, 2024 at 3:14 AM
I have a patient, he is a manager at a fast food restaurant. He had frequently relapsing minimal change disease as a kid and now has FSGS. We are treating him with MMF. He has health insurance. His out of pocket cost for MMF went zero dollars to $1000 a month. He stopped the MMF.
Tsetse fly, Trypanosoma brucei rhodesiense, African sleeping sickness. FSGS/HIVAN. APOL1 dominates to the Elite8. #NephMadness
November 16, 2024 at 5:27 AM
Tsetse fly, Trypanosoma brucei rhodesiense, African sleeping sickness. FSGS/HIVAN. APOL1 dominates to the Elite8. #NephMadness
When I worked in local radio we described such stories as FSGs - for “fucking stupid gits.”
January 24, 2025 at 9:09 AM
When I worked in local radio we described such stories as FSGs - for “fucking stupid gits.”
A few more days to register to the first ever, recurrent FSGS conference!
If you are not blown away by the program, come for the food :)
#rFSGS #FSGS #raredisease #nephsky #medsky #skyneph @gbadegesinlab.bsky.social @kidneyomicsamps.bsky.social @opeyemiolabisi.bsky.social @alessiafornoni.bsky.social
If you are not blown away by the program, come for the food :)
#rFSGS #FSGS #raredisease #nephsky #medsky #skyneph @gbadegesinlab.bsky.social @kidneyomicsamps.bsky.social @opeyemiolabisi.bsky.social @alessiafornoni.bsky.social
🚨 We are officially two weeks out from the #rFSGSConference! 🚨
Reserve your spot so you can join us in Washington, DC to discuss #rFSGS research, funding, and treatments. Register today: www.scgcorp.com/rFSGS2024/Re...
Reserve your spot so you can join us in Washington, DC to discuss #rFSGS research, funding, and treatments. Register today: www.scgcorp.com/rFSGS2024/Re...
November 26, 2024 at 2:14 AM
A few more days to register to the first ever, recurrent FSGS conference!
If you are not blown away by the program, come for the food :)
#rFSGS #FSGS #raredisease #nephsky #medsky #skyneph @gbadegesinlab.bsky.social @kidneyomicsamps.bsky.social @opeyemiolabisi.bsky.social @alessiafornoni.bsky.social
If you are not blown away by the program, come for the food :)
#rFSGS #FSGS #raredisease #nephsky #medsky #skyneph @gbadegesinlab.bsky.social @kidneyomicsamps.bsky.social @opeyemiolabisi.bsky.social @alessiafornoni.bsky.social
JCI Insight - Sparsentan improves glomerular hemodynamics, cell functions, and tissue repair in a mouse model of FSGS https://insight.jci.org/articles/view/177775
JCI Insight -
Sparsentan improves glomerular hemodynamic...
insight.jci.org
December 8, 2024 at 10:58 PM
JCI Insight - Sparsentan improves glomerular hemodynamics, cell functions, and tissue repair in a mouse model of FSGS https://insight.jci.org/articles/view/177775
Sparsentan for FSGS isn’t dead yet… ir.travere.com/news-release...
ir.travere.com
February 12, 2025 at 1:13 PM
Sparsentan for FSGS isn’t dead yet… ir.travere.com/news-release...
Looking forward to join this #Alport group for some quality time travel/conference :)
#FSGS #genetics
#FSGS #genetics
Having a fabulous Bluesky day in Japan! Trip to Minamata with team #Alport & family @moumitabarua.bsky.social @jeffminerphd.bsky.social @alportuk.bsky.social
March 20, 2025 at 10:50 AM
Asked my husband to fill a #NephMadness bracket- he will be my blinded control, as he has nothing to do with medicine. He said that renal denervation sounds poetic (compared to bunch of random letters in FSGS) 😅
March 31, 2025 at 10:39 AM
Asked my husband to fill a #NephMadness bracket- he will be my blinded control, as he has nothing to do with medicine. He said that renal denervation sounds poetic (compared to bunch of random letters in FSGS) 😅
4/ But how APOL1 can cause CKD?
The development of focal segmental glomerulosclerosis (FSGS), which is a leading cause of end-stage kidney disease (ESKD) in African Americans, characterizes APOL1-mediated nephropathy
#NephJC
https://pubmed.ncbi.nlm.nih.gov/35217848/
The development of focal segmental glomerulosclerosis (FSGS), which is a leading cause of end-stage kidney disease (ESKD) in African Americans, characterizes APOL1-mediated nephropathy
#NephJC
https://pubmed.ncbi.nlm.nih.gov/35217848/
November 17, 2024 at 10:13 AM
4/ But how APOL1 can cause CKD?
The development of focal segmental glomerulosclerosis (FSGS), which is a leading cause of end-stage kidney disease (ESKD) in African Americans, characterizes APOL1-mediated nephropathy
#NephJC
https://pubmed.ncbi.nlm.nih.gov/35217848/
The development of focal segmental glomerulosclerosis (FSGS), which is a leading cause of end-stage kidney disease (ESKD) in African Americans, characterizes APOL1-mediated nephropathy
#NephJC
https://pubmed.ncbi.nlm.nih.gov/35217848/
🧬 FSGS affects far too many in silence. Nearly 60% of cases impact Black Americans.
🎙️ On Friday, June 13th, we’re talking real stories, real policy, real change.
🕛 12 PM ET
📲 Register: bit.ly/NMQF0613
#FSGS #RareKidneyDisease #BlackHealthMatters #KidneyEquity #NMQF
🎙️ On Friday, June 13th, we’re talking real stories, real policy, real change.
🕛 12 PM ET
📲 Register: bit.ly/NMQF0613
#FSGS #RareKidneyDisease #BlackHealthMatters #KidneyEquity #NMQF
June 11, 2025 at 1:28 PM
🧬 FSGS affects far too many in silence. Nearly 60% of cases impact Black Americans.
🎙️ On Friday, June 13th, we’re talking real stories, real policy, real change.
🕛 12 PM ET
📲 Register: bit.ly/NMQF0613
#FSGS #RareKidneyDisease #BlackHealthMatters #KidneyEquity #NMQF
🎙️ On Friday, June 13th, we’re talking real stories, real policy, real change.
🕛 12 PM ET
📲 Register: bit.ly/NMQF0613
#FSGS #RareKidneyDisease #BlackHealthMatters #KidneyEquity #NMQF